Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Semaglutide and Canagliflozin show similar effects on body composition
Last updated September 12, 2026
Key finding
Total fat mass was reduced by 3.4 kg with semaglutide.
This study compared the effects of Semaglutide and Canagliflozin on body composition in adults with Type 2 Diabetes, finding greater reductions in fat and lean mass with Semaglutide.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study compared the effects of Semaglutide and Canagliflozin on body composition in adults with Type 2 Diabetes, finding greater reductions in fat and lean mass with Semaglutide.
Clinical relevance
Understanding the differential effects of Semaglutide and Canagliflozin on body composition is crucial for clinicians managing Type 2 Diabetes. These findings suggest that Semaglutide may offer superior benefits in reducing body fat and lean mass, which can influence treatment decisions and improve patient outcomes.
Keep in mind
Unclear effectiveness of interventions due to lack of p-values. Limited generalizability due to specific population characteristics. Potential confounding factors not measured.
Published in
Journal Reference
Publication details and source links for this paper.
Rory JM, Andrei-Mircea C, Juan PF, et al. Effects of Semaglutide vs Canagliflozin on Body Composition in Adults with Type 2 Diabetes. Diabetologia. 2020;63(3):473-485. doi:10.1007/s00125-019-05065-8
Main Effects
Semaglutide reduced total fat mass by 3.4 kg.
Canagliflozin reduced total fat mass by 2.6 kg.
Semaglutide reduced total lean mass by 2.3 kg.
Canagliflozin reduced total lean mass by 1.5 kg.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Canagliflozin, Semaglutide and Body fat mass, Lean body mass, Percentage change in visceral fat mass.
This study contributes evidence to
Primary intervention
Canagliflozin
Primary outcomes
- Body fat mass
- Lean body mass
- Percentage change in visceral fat mass
Primary intervention
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
6
Evidence pairs
6
Relationships
4
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 68
4
Related topics
6
Evidence pairs
663
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 6 evidence relationships
- Includes primary outcome data
- Linked to 4 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
GLP-1 Receptor Agonists and Body Composition
Related evidence
Evidence relationship
SGLT2 Inhibitors and Body Composition
Save evidence
Evidence topic
Body Composition
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 25
- Negative
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerPercentage change in visceral fat mass
Canagliflozin → Percentage change in visceral fat mass
Canagliflozin → Percentage change in visceral fat mass
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 25
- Negative
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerPercentage change in visceral fat mass
Semaglutide → Percentage change in visceral fat mass
Semaglutide → Percentage change in visceral fat mass
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Semaglutide led to a 3.4 kg reduction in total fat mass.
- Canagliflozin resulted in a 2.6 kg reduction in total fat mass.
- Total lean mass decreased by 2.3 kg with Semaglutide.
Who this applies to
- Adults with Type 2 Diabetes.
- Participants receiving pharmacological treatment for diabetes.
Keep in Mind
- Results may not be applicable to populations outside the study.
- Effectiveness data are unclear due to missing p-values.
- Further research is needed to confirm findings in diverse populations.
Between the Lines
- Unclear effectiveness of interventions due to lack of p-values.
- Limited generalizability due to specific population characteristics.
- Potential confounding factors not measured.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and Body Composition, SGLT2 Inhibitors and Body Composition.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
SGLT2 Inhibitors → Body Composition
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceMedications
SGLT2 Inhibitors → Body Composition
Medications
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 25
- Negative
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Canagliflozin and Body fat mass
Intervention: CanagliflozinOutcome: Body fat mass
1 results
All studies on Canagliflozin and Lean body mass
Intervention: CanagliflozinOutcome: Lean body mass
1 results
All studies on Canagliflozin
Intervention: Canagliflozin
1 results
All studies measuring Body fat mass
Outcome: Body fat mass
1 results
All studies measuring Lean body mass
Outcome: Lean body mass
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Do GLP-1 Receptor Agonists improve body composition?
Strong Evidence
GLP-1 Receptor Agonists may improve body composition.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body fat mass
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
- 2
Lean body mass
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | moderate negative | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 12 supporting studies with consistent results and a positive effect signal.
Do SGLT2 Inhibitors improve body composition?
Strong Evidence
SGLT2 Inhibitors appear to improve body composition.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body fat mass
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
- 2
Lean body mass
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | moderate negative | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies with consistent results and a positive effect signal.
Does Canagliflozin improve percentage change in visceral fat mass?
Emerging Evidence
Canagliflozin appears to improve percentage change in visceral fat mass.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Percentage change in visceral fat mass
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Semaglutide improve percentage change in visceral fat mass?
Emerging Evidence
Semaglutide appears to improve percentage change in visceral fat mass.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Percentage change in visceral fat mass
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Canagliflozin slows kidney function decline in type 2 diabetes.Semaglutide may reduce cardiovascular events in non-diabetic patients.Oral semaglutide reduces cardiovascular events in type 2 diabetesSemaglutide improves insulin sensitivity in adolescents with obesityHigher semaglutide doses improve glucose control in type 2 diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.